Skip to main content

A screening protocol to determine tumor antigen expression and HLA sub-type ofr eligibility determination for clinical trials evaluating the safety and efficacy of Autologous T Cell expressing enhance

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Adaptimmune Limited

Start Date

February 1, 2016

End Date

January 31, 2023
 

Administered By

Duke Cancer Institute

Awarded By

Adaptimmune Limited

Start Date

February 1, 2016

End Date

January 31, 2023